A New Saquinavir Mesylate-Sodium Decyl Sulfate Salt Discovered by Serendipity during an Anomalous Dissolution Test.
dissolution
recrystallization
saquinavir mesylate
single crystal
sodium decyl sulfate
Journal
Pharmaceutical research
ISSN: 1573-904X
Titre abrégé: Pharm Res
Pays: United States
ID NLM: 8406521
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
14
10
2021
accepted:
11
01
2022
pubmed:
23
1
2022
medline:
17
3
2022
entrez:
22
1
2022
Statut:
ppublish
Résumé
To understand the anomalous behavior of Saquinavir Mesylate (SQVM) in sodium decyl sulfate (SDS) medium during a dissolution test through a crystallographic analysis of the crystal obtained. As a result, it will be possible to elucidate its crystal structure and carry out a complete solid-state characterization of the API. The solid form obtained was characterized by a structural analysis through X-ray single crystal and powder diffraction. The crystallographic structures of the new salt and the SQVM were compared. In addition, a complete solid-state characterization of SQVM raw material was carried out by techniques such as diffuse reflectance infrared Fourier transform spectroscopy (DRIFTS), Raman spectroscopy, scanning electron microscopy and a dissolution method. A new salt consisting of SQVM and SDS was crystallized and its crystal structure was elucidated and reported herein for the first time. The anionic part of SDS interacts with the cationic segment of SQVM to obtain a new salt designated as SQV-DS, which precipitates. The main difference between the two structures occurs in the c-axis expansion, which increases from 15.966 (5) to 21.1924 (14), respectively. Some of the strategies to enhance the dissolution rate of poorly aqueous soluble APIs include the use of surfactants such as SDS in the dissolution medium, as well as in the formulated products. However, there have been constant reports of a dissolution rate slowdown by some surfactants. The interaction mechanisms between the APIs and the dissolution medium containing surfactants need to be carefully investigated in current pharmaceutical formulations. Graphical Abstract.
Identifiants
pubmed: 35064418
doi: 10.1007/s11095-022-03167-4
pii: 10.1007/s11095-022-03167-4
doi:
Substances chimiques
Pharmaceutical Preparations
0
Sulfates
0
Sodium
9NEZ333N27
Saquinavir
L3JE09KZ2F
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
189-200Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int J Pharm. 2011;420:1–10.
doi: 10.1016/j.ijpharm.2011.08.032
Kalepu S, Nekkanti V. Insoluble drug delivery strategies: review of recent advances and business prospects. Acta Pharm Sin B. 2015;5:442–53. https://doi.org/10.1016/j.apsb.2015.07.003 .
doi: 10.1016/j.apsb.2015.07.003
pubmed: 26579474
pmcid: 4629443
Chakraborty S, Shukla D, Jain A, Mishra B, Singh S. Assessment of solubilization characteristics of different surfactants for carvedilol phosphate as a function of pH. J Colloid Interface Sci. 2009;335:242–9.
doi: 10.1016/j.jcis.2009.03.047
Aljaberi A, Chatterji A, Dong Z, Shah NH, Malick W, Singhal D, Sandhu HK. Understanding and optimizing the dual excipient functionality of sodium lauryl sulfate in tablet formulation of poorly water soluble drug: wetting and lubrication. Pharm Dev Technol. 2013;18:490–503.
doi: 10.3109/10837450.2012.723717
Fandaruff C, Chelazzi L, Braga D, Cuffini SL, Silva MAS, Resende JALC, Dichiarante E, Grepioni F. Isomorphous salts of anti-HIV saquinavir mesylate: exploring the effect of anion-exchange on its solid-state and dissolution properties. Cryst Growth Des. 2015;15:5233–9. https://doi.org/10.1021/acs.cgd.5b00696 .
doi: 10.1021/acs.cgd.5b00696
Hoffmeister CRD, Fandaruff C, da Costa MA, Cabral LM, Pitta LR, Bilatto SER, Prado LD, Corrêa DS, Tasso L, Silva MAS, Rocha HVA. Efavirenz dissolution enhancement III: colloid milling, pharmacokinetics and electronic tongue evaluation. Eur J Pharm Sci. 2017;99:310–7. https://doi.org/10.1016/j.ejps.2016.12.0327 .
doi: 10.1016/j.ejps.2016.12.0327
pubmed: 28042101
Hamed R, Alnadi SH, Awadallah A. The effect of enzymes and sodium lauryl sulfate on the surface tension of dissolution media: toward understanding the solubility and dissolution of carvedilol. AAPS PharmSciTech. 2020;21:146.
doi: 10.1208/s12249-020-01683-3
Jon DI, Chang DL. Interactions between an amine functional polymer and an anionic surfactant. J Soc Cosmet Chem. 1990;41:213–25.
Nokhodchi A, Norouzi-Sani S, Siahi-Shadbad M-R, Lotfipoor F, Saeedi M. The effect of various surfactants on the release rate of propranolol hydrochloride from hydroxypropylmethylcellulose (HPMC)-Eudragit matrices. Eur J Pharm Biopharm. 2002;54:349–56.
doi: 10.1016/S0939-6411(02)00120-0
Jain A, Ran Y, Yalkowsky SH. Effect of pH-sodium lauryl sulfate combination on solubilization of PG-300995 (an anti-HIV agent): a technical note. AAPS PharmSciTech. 2004;5:65–7.
doi: 10.1208/pt050345
Bhattachar SN, Risley DS, Werawatganone P, Aburub A. Weak bases and formation of a less soluble lauryl sulfate salt/complex in sodium lauryl sulfate (SLS) containing media. Int J Pharm. 2011;412:95–8.
doi: 10.1016/j.ijpharm.2011.04.018
Desai D, Wong B, Huang Y, Ye Q, Tang D, Guo H, Huang M, Timmins P. Surfactant-mediated dissolution of metformin hydrochloride tablets: wetting effects versus ion pairs diffusivity. J Pharm Sci. 2014;103:920–6.
doi: 10.1002/jps.23852
Guo Y, Wang C, Dun J, Du L, Hawley M, Sun CC. Mechanism for the reduced dissolution of ritonavir tablets by sodium lauryl sulfate. J Pharm Sci. 2019;108:516–24.
doi: 10.1016/j.xphs.2018.10.047
Huang Z, Parikh S, Fish WP. Interactions between a poorly soluble cationic drug and sodium dodecyl sulfate in dissolution medium and their impact on in vitro dissolution behavior. Int J Pharm. 2018;535:350–9.
doi: 10.1016/j.ijpharm.2017.10.063
Dressman JB, Amidon GL, Reppas C, Shah VP. Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms. Pharm. Res. 1998. p. 11–22. https://doi.org/10.1023/A:1011984216775 .
Nicolaides E, Galia E, Efthymiopoulos C, Dressman JB, Reppas C. Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data. Pharm Res. 1999;16(12):1876–82.
doi: 10.1023/A:1018959511323
Zaborenko N, Shi Z, Corredor CC, Smith-Goettler BM, Zhang L, Hermans A, Neu CM, Alam MA, Cohen MJ, Lu X, Xiong L, Zacour BM. First-principles and empirical approaches to predicting in vitro dissolution for pharmaceutical formulation and process development and for product release testing. AAPS J. 2019;21:32.
doi: 10.1208/s12248-019-0297-y
Lu Y, Kim S, Park K. In vitro–in vivo correlation: perspectives on model development. Int J Pharm. 2011;418:142–8.
doi: 10.1016/j.ijpharm.2011.01.010
Pathak SM, Musmade P, Dengle S, Karthik A, Bhat K, Udupa N. Enhanced oral absorption of saquinavir with methyl-Beta-Cyclodextrin—preparation and in vitro and in vivo evaluation. Eur J Pharm Sci. 2010;41:440–51.
doi: 10.1016/j.ejps.2010.07.013
Mahajan HS, Pingale MH, Agrawal KM. Solubility and dissolution enhancement of saquinavir mesylate by inclusion complexation technique. J Incl Phenom Macrocycl Chem. 2013;76:467–72.
doi: 10.1007/s10847-012-0269-7
Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. An Off. J. Am. Assoc. Pharm. Sci. 1995;12: 413–420.
Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm. 2004;58:265–78.
doi: 10.1016/j.ejpb.2004.03.001
Beloqui A, Solinís MÁ, Gascón AR, Del Pozo-Rodríguez A, Des Rieux A, Préat V. Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J Control Release. 2013;166:115–23. https://doi.org/10.1016/j.jconrel.2012.12.021 .
doi: 10.1016/j.jconrel.2012.12.021
pubmed: 23266764
Bruker. APEX II, Data Collection Software, version 2011.8–0. Madison, WI: Bruker AXS Inc.; 2011.
Bruker. Bruker APEX2, SAINT and SADABS. Madison, WI: Bruker AXS Inc.; 2009.
Sheldrick GM. SHELXT – integrated space-group and crystal-structure determination. Acta Crystallogr Sect A Found Adv. 2015;71:3–8 http://scripts.iucr.org/cgi-bin/paper?S2053273314026370 .
doi: 10.1107/S2053273314026370
Sheldrick GM. A short history of SHELX. Acta Crystallogr Sect A Found Crystallogr. 2008;64:112–22. https://doi.org/10.1107/S0108767307043930 .
doi: 10.1107/S0108767307043930
Dolomanov O V., Bourhis LJ, Gildea RJ, Howard JAK, Puschmann H. OLEX2 : a complete structure solution, refinement and analysis program. J Appl Crystallogr 2009;42:339–341.
Macrae CF, Edgington PR, McCabe P, Pidcock E, Shields GP, Taylor R, Towler M, van de Streek J. Mercury : visualization and analysis of crystal structures. J Appl Crystallogr. 2006;39:453–7.
doi: 10.1107/S002188980600731X
FDA. Guindance for Industry Q2B Validation of Analytical Procedures: Methodology https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q2a-text-validation-analytical-procedures . Accessed 28 June 2021.
Branham ML, Moyo T, Govender T. Preparation and solid-state characterization of ball milled saquinavir mesylate for solubility enhancement. Eur J Pharm Biopharm. 2012;80:194–202.
doi: 10.1016/j.ejpb.2011.08.005
Vippagunta SR, Brittain HG, Grant DJW. Crystalline solids. Adv Drug Deliv Rev. 2001;48:3–26.
doi: 10.1016/S0169-409X(01)00097-7
USP-NF 2020 - Issue 2 - United States Pharmacopeia. Saquinavir Mesylate. Rockville, United States Convention, 2020.
Farmacopea Argentina. 2003. https://www.argentina.gob.ar/sites/default/files/libro_segundo.pdf . .
ANVISA. Farmacopeia Brasileira. 2019. https://www.gov.br/anvisa/pt-br/assuntos/farmacopeia/farmacopeia-brasileira/arquivos/7987json-file-1 . Accessed 28 June 2021.
USP, 2007 - United States Pharmacopeia, The (USP) 30 ed., Rockville, United States Convention, 2007.
Fotaki N, Brown W, Kochling J, Chokshi H, Miao H, Tang K, Gray V. Rationale for selection of dissolution media: three case studies. Dissolution Technol. 2013;20:6–13.
doi: 10.14227/DT200313p6
Park S-H, Choi H-K. The effects of surfactants on the dissolution profiles of poorly water-soluble acidic drugs. Int J Pharm. 2006;321:35–41.
doi: 10.1016/j.ijpharm.2006.05.004
Phillips DJ, Pygall SR, Cooper VB, Mann JC. Overcoming sink limitations in dissolution testing: a review of traditional methods and the potential utility of biphasic systems. J Pharm Pharmacol. 2012;64:1549–59.
doi: 10.1111/j.2042-7158.2012.01523.x
Pinto EC, Cabral LM, de Sousa VP. Development of a discriminative intrinsic dissolution method for Efavirenz. Dissolution Technol. 2014;21:31–40.
doi: 10.14227/DT210214P31
Panikumar AD, Venkat Raju Y, Sunitha G, Sathesh Babu PR, Subrahmanyam CVS. Development of biorelevant and discriminating method for dissolution of efavirenz and its formulations. Asian J Pharm Clin Res. 2012;5:220–3.
Honório T da S, Pinto EC, Rocha HVA, Esteves VSD, dos Santos TC, Castro HCR, et al. in vitro–in vivo correlation of Efavirenz tablets using GastroPlus®. AAPS PharmSciTech 2013;14:1244–1254. https://doi.org/10.1208/s12249-013-0016-4 .
Ruddy SB, Matuszewska BK, Grim YA, Ostovic D, Storey DE. Design and characterization of a surfactant-enriched tablet formulation for oral delivery of a poorly water-soluble immunosuppressive agent. Int J Pharm. 1999;182:173–86.
doi: 10.1016/S0378-5173(99)00056-3
Fandaruff C, Rauber GS, Araya-Sibaja AM, Pereira RN, De Campos CEM, Rocha HVA, et al. Polymorphism of anti-HIV drug efavirenz: investigations on thermodynamic and dissolution properties. Cryst Growth Des. 2014;14:4968–75. https://doi.org/10.1021/cg500509c .
doi: 10.1021/cg500509c
Fandaruff C, Segatto Silva MA, Galindo Bedor DC, De Santana DP, Rocha HVA, Rebuffi L, et al. Correlation between microstructure and bioequivalence in anti-HIV drug Efavirenz. Eur J Pharm Biopharm. 2015;91:52–8. https://doi.org/10.1016/j.ejpb.2015.01.020 .
doi: 10.1016/j.ejpb.2015.01.020
pubmed: 25661587
Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release. 2001;73:137–72.
doi: 10.1016/S0168-3659(01)00299-1
Rangel-Yagui C de O, Pessoa A, Tavares LC. Micellar solubilization of drugs J Pharm Pharm Sci 2005;8:147–163.
Caon T, Konig RA, Da Cruz ACC, Cardoso SG, Campos CEM, Cuffini SL, et al. Development and physicochemical characterization of saquinavir mesylate solid dispersions using Gelucire 44/14 or PEG 4000 as carrier. Arch Pharm Res. 2013;36:1113–25. https://doi.org/10.1007/s12272-013-0142-2 .
doi: 10.1007/s12272-013-0142-2
pubmed: 23700292